Nancy Lill, PhD
Dr. Nancy Lill's current research focus is identifying mechanisms of protein and drug action that can be manipulated for the development of new anticancer therapies.
She works with Raymond J. Hohl, MD, PhD, director of Penn State Cancer Institute, on synthetic versions of natural compounds known as the schweinfurthins.
Ongoing mechanistic studies involve molecular and cell biology assays of: receptor tyrosine kinase signaling (as for the EGF receptor); protein and lipid trafficking; tumor suppressor inactivation; and cell metabolism.
- Epidermal Growth Factor Receptor
- Protein-Tyrosine Kinases
- Oncogene Proteins
- Viral Tumor Antigens
- Simian virus 40